Breaking News

Longboard Pharma Selects Societal CDMO to Support Clinical Development of LP352

To provide technology transfer and analytical method validation activities to support Longboard’s lead asset.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Societal CDMO, Inc. has been selected by Longboard Pharmaceuticals, Inc. to provide CDMO services, including technology transfer and analytical method validation activities to support Longboard’s lead asset, LP352, a 5-HT2C receptor superagonist. LP352 is currently being evaluated in a Phase 1b/2a basket trial in participants with developmental and epileptic encephalopathies or DEEs, such as Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, CDKL5 deficiency disorder, SCN2A-re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters